APR 07, 2016 10:30 AM PDT

Airbrushing the Poster Child: How ACOG's 2016 cervical cancer screening practice bulletin may impact molecular testing

C.E. CREDITS: P.A.C.E. CE
Speakers
  • Senior Director, Scientific Affairs at Roche Molecular Diagnostics
    Biography
      Dr. Ed Baker trained received his medical training in the Loma Linda University system. After completing his specialty training in Obstetrics and Gynecology, he practiced in the San Francisco bay area as a community physician for nearly 10 years. In 2002 he became interested in drug development and took a position with Organon Pharmaceuticals which was one of the most active companies focused on Women's health and eventually became the head of the women's health franchise Medical Affairs team.
      Dr. Baker has been involved in the development and registration of dozens of products for women's health and often lectures and writes on a variety of topics related to women's health. He has taken leadership positions for companies focused on areas outside of women's health. Prior to his current position he was head of Medical Affairs at Actelion Pharmaceuticals, a company that focused its efforts on rare diseases. He was attracted to his current position at Roche Molecular diagnostics because it presents a great opportunity to help shift a longstanding paradigm in cervical cancer screening. Dr. Baker remains a board certified OB/GYN and holds an appointment as Associate Professor of Medicine in the OB/GYN department at UC Davis.

    Abstract:

    Cervical cancer screening has been the 20th century poster child for preventative screening.  This presentation is a gynecologist’s perspective on its continuing evolution –both as a great success and an opportunity for improvement.    Dr Baker will focus on the transition from experience based to data driven development of guidelines for physicians.  He will also reflect on the challenges for molecular laboratories.   Their anticipation of changes in screening practice and potential impact to their range of services including consultative role to OB/Gyn physicians.  
     
    Learning objectives:
    1) The attendee will understand how and why the approach to cervical cancer screening is evolving.
    2) The attendee will understand how these changes might impact the molecular lab and it's relationship with OB/GYNs.
     
     


    Show Resources
    You May Also Like
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    JUN 20, 2018 10:00 AM EDT
    C.E. CREDITS
    JUN 20, 2018 10:00 AM EDT
    DATE: June 20, 2018TIME: 07:00AM PDT, 10:00AM EDTIntroducing GE’s New Lyo-StableTM service. Sepsis is one of the top challenges facing hospitals in terms of clinical outcomes...
    Loading Comments...